MDT perspectives on tailoring second-line treatment selection to each patient with relapsed SCLC
touchMDT for touchONCOLOGY
Listen to key experts from a multidisciplinary team discuss how side effects of SCLC treatment and patient performance status impact treatment selection and prognosis, and the potential for molecular classification to determine future treatment options
The multidisciplinary team:
Medical oncologist: Dr Barbara Melosky, University of British Columbia, Vancouver, Canada
Pulmonologist: Dr Christine Argento, Johns Hopkins University, Baltimore, MD
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Jazz…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.